iECURE
Matthew Hall serves as the Vice President of Clinical Operations at iECURE, inc. since May 2022, bringing extensive experience in clinical development and operations across multiple pharmaceutical companies. Prior roles include Vice President and Head of Clinical Development Operations at Marinus Pharma, and Director of Medical Operations at Teva Pharmaceuticals, where significant contributions included launching new departments, overseeing clinical strategies in therapeutic areas such as Women’s Health, and managing operational performance for numerous clinical trials. Matthew has held leadership positions across various companies, including Barr Laboratories and PharmaNet Development Group, demonstrating a strong ability to drive operational excellence and foster collaborative relationships within clinical operations. Matthew holds a Bachelor of Science degree in Human Biology from the University of Utah.
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.